Abstract:
Objective
To evaluate the efficacy and safety of compound Danshen injection for Henoch-Schonlein purpura(HSP).
Methods
Clinical randomized controlled trials(RCT) were collected by searching Pubmed, WEB of SCIENCE, the Cochrane Library, CNKI, VIP and Wanfang Data from their inception to November 30, 2016. Two researchers screen the literatures and selected the data according to inclusion and exclusion criteria. The quality of included studies was assessed according to the criteria recommended Cochrane Collaboration. Meta-analysis was performed by using RevMan 5.3 software.
Results
Ten trials(n=768) were included. The results of Meta-analysis demonstrated that, the efficiency of compound Danshen injection adjuvant therapy for HSP was better, including the total effective rate, the time of erythra regression time, the relief time of clinical symptoms of joints and the relief time of clinical gastrointestinal symptoms(P<0.05); there were no serious adverse effects in the treatment.
Conclusion
Compared with routine treatment, compound Danshen injection therapy might be a better choice for HSP with more remarkable efficacy and few adverse effects. However, the quality of the included literature is low, so high-quality clinical trials are needed to verify its effect.

Key words: Henoch-Schonlein purpura, Compound Danshen injection, Meta-analysis, Children